This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129:2224–32.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372:1430–40.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.
Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833–43 e835.
Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131:1955–9.
Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128:1940–3.
Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid malignancies. Clin Infect Dis. 2018;67:687–92.
Bercusson A, Colley T, Shah A, Warris A, Armstrong-James D. Ibrutinib blocks Btk-dependent NF-kB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132:1985–8.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.
Tuccori M, Focosi D, Blandizzi C, Pelosini M, Montagnani S, Maggi F, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist. 2010;15:1214–9.
Lecube A, Pachon G, Petriz J, Hernandez C, Simo R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PloS ONE. 2011;6:e23366.
Uribe-Querol E, Rosales C. Control of phagocytosis by microbial pathogens. Front Immunol. 2017;8:1368.
Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–96.
Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw: JNCCN. 2016;14:882–913.
Acknowledgements
We would like to thank the Ohio State University Division of Hematology for support of this project. We would also like to acknowledge our colleagues who provided the clinical care for the included patients. Research reported in this publication was supported in part by the Ohio State University Comprehensive Cancer Center and the National Institutes of Health under grant number P30 CA016058. This work was also supported in part by K23 CA178183, R01 CA197870, and R35 CA197734.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have the following disclosures: KAR received research funding from Genentech and consults for Acerta Pharma. SAB is on a speakers’ bureau for Janssen and Pharmacyclics. JCB receives research funding from Genentech, Acerta Pharma, Pharmacyclics, and Janssen. JAW received honoraria from Janssen, has consulted for Janssen, and receives research funding from MorphoSys, Karyopharm Therapeutics, and AbbVie. FTA has consulted for AbbVie, Gilead Sciences, AstraZeneca, Sunesis, Genentech, and Janssen, served on the speakers’ bureau for Abbvie and AstraZeneca, and received research funding from Pharmacyclics. LM, QZ, TEW, ZEB, TG, LBL, FL, PS, AS, and MS declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Rogers, K.A., Mousa, L., Zhao, Q. et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia 33, 2527–2530 (2019). https://doi.org/10.1038/s41375-019-0481-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-019-0481-1
This article is cited by
-
Severe infections requiring intensive care unit admission in patients receiving ibrutinib for hematological malignancies: a groupe de recherche respiratoire en réanimation onco-hématologique (GRRR-OH) study
Annals of Intensive Care (2023)
-
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
Experimental Hematology & Oncology (2023)
-
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Journal of Hematology & Oncology (2022)
-
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
Leukemia (2022)
-
The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis
Blood Cancer Journal (2022)